Publication | Closed Access

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

Hematological MalignancyAnthracycline-based TherapyLymphoid NeoplasiaMedicineImmunologyPathologyHigh-dose ChemotherapySakk 38/08ImmunotherapyOncologyRadiation Oncology